Crossmark

One vs. 2 vs. ≥3 TET2 mutations in chronic myelomonocytic leukemia: co-mutation patterns and prognostic relevance in the context of contemporary prognostic models including BLAST-mol and CPSS-mol

Crossref DOI link: https://doi.org/10.1038/s41408-026-01500-3

Published Online: 2026-04-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Yousuf, Muhammad

Fathima, Saubia

Alsugair, Ali Khalid A.

Wu, Samuel J. https://orcid.org/0000-0002-7958-8294
Abdelmagid, Maymona G.

Patel, Shraddha P.

Faldu, Priyansh C.

Abdelaziz, Rania M.

Csizmar, Clifford M. https://orcid.org/0000-0002-1221-8854
Mangaonkar, Abhishek A. https://orcid.org/0000-0003-2458-9887
Zepeda Mendoza, Cinthya J. https://orcid.org/0000-0002-0434-4965
Reichard, Kaaren K. https://orcid.org/0000-0001-5439-0778
Viswanatha, David S.

He, Rong https://orcid.org/0000-0001-6116-8163
Pardanani, Animesh

Gangat, Naseema https://orcid.org/0000-0002-9104-6172
Patnaik, Mrinal S. https://orcid.org/0000-0001-6998-662X
Tefferi, Ayalew https://orcid.org/0000-0003-4605-3821
License Information

Text and Data Mining valid from 2026-04-04

Version of Record valid from 2026-04-04
More Information

Article History

Received: 12 January 2026

Revised: 6 March 2026

Accepted: 25 March 2026

First Online: 4 April 2026

Competing interests

: The authors declare no competing interests.

: This study was approved by the Institutional Review Board of the Mayo Clinic (IRB #12-003574) and was conducted in accordance with the Declaration of Helsinki and other relevant guidelines and regulations. Informed consent was obtained from all participants.

Document is current

Any future updates will be listed below